10 Stocks to Buy Before the Next Pandemic
In this article, we discuss the 10 stocks to buy before the next pandemic.
Alnylam Pharmaceuticals Inc. (ALNY)
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 1,300,000 | $212,277 | +21% | 3.87% |
| 2. | Farallon Capital Thomas Steyer | 1,023,873 | $167,188 | -14% | 0.88% |
| 3. | Casdin Capital Eli Casdin | 1,000,000 | $163,290 | 7.32% | |
| 4. | Holocene Advisors Brandon Haley | 799,222 | $130,505 | +11% | 0.68% |
| 5. | Deep Track Capital David Kroin | 463,663 | $75,712 | 4.85% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $71.87 | 297,501 | Large Shareholder | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | Officer | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | Director | 27,900 | 2016-10-13 | Filing | |
| $58.36 | 2,000 | Director | 4,000 | 2016-03-09 | Filing | |
| $69.75 | 205,030 | Large Shareholder | 10,256,633 | 2016-02-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $178.60 | 175 | Director | 1,000 | 2022-04-01 | Filing | |
| $177.58 | 825 | Director | 1,175 | 2022-04-01 | Filing | |
| $176.51 | 526 | Director | 2,000 | 2022-04-01 | Filing | |
| $174.33 | 90 | Director | 2,526 | 2022-04-01 | Filing | |
| $173.06 | 642 | Director | 2,616 | 2022-04-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 605,165 | $98,817,395 | 0.04% | |
| 2. | 66,700 | $10,891,443 | 0.01% | |
| 3. | 21,355 | $3,487,058 | 0.02% | |
| 4. | 16,045,316 | $2,620,040 | 0.2% | |
| 5. | 10,829,144 | $1,768,291 | 0.04% |
News See All
5 Best Drug Stocks To Buy Now
Evotec SE (NYSE:EVO) is a German drug discovery, pharmaceutical, and biotechnology company that produces drug candidates for diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation...
Was The Smart Money Right About Alnylam Pharmaceuticals, Inc. (ALNY)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Are Piling Into Alnylam Pharmaceuticals, Inc. (ALNY)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
5 Pharmaceutical Stocks to Buy According to Brandon Haley’s Holocene Advisors
In this article, we take a look at the 5 pharmaceutical stocks to buy according to Brandon Haley’s Holocene Advisors.
10 Best Healthcare Stocks to Buy According to Greg Martinez’s Parkman Healthcare Partners
In this article, we discuss the 10 best healthcare stocks to buy according to Greg Martinez's Parkman Healthcare Partners.
Analysts are Increasing Price Targets of Tesla and 9 Other Stocks
In this article, we discuss the 10 stocks that analysts are increasing price targets of.
11 Best Genomic Stocks to Buy Now
Genomics is a branch of biology that studies the structure, function, evolution, mapping, and editing of genomes, which refer to the complete set of DNA of an organism, as opposed to genetics, which is...
Alnylam Pharmaceuticals, Inc. (ALNY) Fell Out Of Favor With Hedge Funds?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June.
5 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie
In this article, we will discuss 5 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie.
Billionaire Hedge Funds
